Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (9)

2024

  1. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

2023

  1. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

2021

  1. Corrigendum to “Corrigendum to Hydroxyethyl starch and acute kidney injury in high-risk patients undergoing cardiac surgery: A prospective multicenter study” [J Clin Anesth 2021 Oct;73:110367] (Journal of Clinical Anesthesia (2021) 73, (S0952818021002063), (10.1016/j.jclinane.2021.110367))

    Journal of Clinical Anesthesia

  2. Hydroxyethyl starch and acute kidney injury in high-risk patients undergoing cardiac surgery: A prospective multicenter study

    Journal of Clinical Anesthesia, Vol. 73

2019

  1. MicroRNA 7 impairs insulin signaling and regulates Aβ levels through posttranscriptional regulation of the insulin receptor substrate 2, insulin receptor, insulin-degrading enzyme, and liver X receptor pathway

    Molecular and Cellular Biology, Vol. 39, Núm. 22

2018

  1. MYC Induces a Hybrid Energetics Program Early in Cell Reprogramming

    Stem Cell Reports, Vol. 11, Núm. 6, pp. 1479-1492

2014

  1. Multicenter study of outcome in relation to the type of resection in rectal cancer

    Diseases of the Colon and Rectum, Vol. 57, Núm. 7, pp. 811-822

2002

  1. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders

    Blood, Vol. 100, Núm. 9, pp. 3121-3127